Organon & Co. (BMV:OGN)

Market Cap	43.27B
Revenue (ttm)	115.57B
Net Income (ttm)	9.19B
Shares Out	n/a
EPS (ttm)	35.07
PE Ratio	4.71
Forward PE	2.51
Dividend	6.83 (4.48%)
Ex-Dividend Date	Nov 20, 2025

Volume	n/a
Average Volume	1,450
Open	152.50
Previous Close	152.50
Day's Range	152.50 - 152.50
52-Week Range	117.00 - 327.00
Beta	n/a
RSI	55.44
Earnings Date	Feb 13, 2026

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OGN

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD